Dose–Response Characteristics in Adolescents with Attention-Deficit/Hyperactivity Disorder Treated with OROS ® Methylphenidate in a 4-Week, Open-Label, Dose-Titration Study
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim of this study was to evaluate dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder (ADHD) treated with once-daily OROS methylphenidate (OROS MPH) during the 4-week, open-label, escalating dose-titration phase of a larger multisite, placebo-controlled trial. Patient factors such as age, height, weight, and baseline symptom severity were evaluated as predictors of selected dose, as was the degree of incremental response with each successive dose escalation. METHODS: Adolescents 13-18 years of age with ADHD underwent a 4-week, open-label, escalating dose-titration trial to determine the minimal effective dose (18, 36, 54, or 72 mg once daily) of OROS to be used in a multiphase, placebo-controlled study (NCT00249353). Both final absolute dose and mean weight-adjusted dose were used to assess predictors of response, using a one-way analysis of variance and regression analyses. RESULTS: The majority of subjects who did not respond at lower doses achieved response at each escalating dose level. Approximately two-thirds of subjects required a dose of 54 mg or greater to achieve improvement criteria. Minimal effective dose correlated modestly with baseline symptom severity. Age, height, and weight did not correlate with absolute dose and accounted for only a small percentage of variance in weight-based dose. Weight was not a major factor in predicting effective dose; however, using weight-adjusted rather than absolute dose proved slightly superior for modeling of adverse effects. CONCLUSIONS: Adolescents required, on average, a higher absolute dose but a lower weight-adjusted dose (mg/kg) of OROS) than was previously reported in children. There were few predictors of optimal dose of OROS other than baseline symptom severity. The increased percentage of adolescent responders at each dose level using this clinically driven approach to titration differs from recent findings from randomized forced dose titration studies in adults with ADHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BARKLEY, R. A., FISCHER, M., EDELBROCK, C. S., & SMALLISH, L. (1990) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199007000-00007 · Cited by 1,507
Biederman, J. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.816 · Cited by 1,498 · cited 1×
“However, adolescents with ADHD differ from children in that they are larger and generally display fewer hyperactive-impulsive symptoms (Barkley et al. 1990; Hart et al. 1995; Biederman et al. 2000).”
Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
Goldman, L. S. (1998) · JAMA · doi:10.1001/jama.279.14.1100 · Cited by 1,082 · cited 1×
“Although parent-rated ADHD-RS scores showed significance in the model and investigator-rated scores did not, these measures are known to be highly inter-correlated (Goldman et al. 1998).”
Committee on Quality Improvement, S. O. A.-D. D. (2000) · Pediatrics · doi:10.1542/peds.105.5.1158 · Cited by 1,076
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · cited 1×
“…of stimulants in adults (Taylor et al. 2000; Spencer et al. 1995; Spencer et al. 2001; Taylor et al. 2001; Adler et al. 2009), and exceeded the threshold of 25% reduction in ADHD symptoms more typically used in studies with children at that time (e.g., Faries et al. 2001; Michelson et al. 2002).”
Self-citationHart, E. L., Lahey, B. B., Loeber, R., Applegate, B., & Frick, P. J. (1995) · Journal of Abnormal Child Psychology · doi:10.1007/bf01447474 · Cited by 590
Wolraich, M. L., Greenhill, L. L., Pelham, W., Swanson, J., Wilens, T., Palumbo, D., Atkins, M., McBurnett, K., Bukstein, O., August, G., et al. (2001) · Pediatrics · doi:10.1542/peds.108.4.883 · Cited by 502
Faraone, S. V., Spencer, T., Aleardi, M., Pagano, C., & Biederman, J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000108984.11879.95 · Cited by 404
Spencer, T. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180020004 · Cited by 402 · cited 3×
“Similar findings have been reported in studies of adults with ADHD (Spencer et al. 1995; Faraone et al. 2004).”
InfluentialNational trends in the treatment of attention deficit hyperactivity disorder
Olfson, M., Gameroff, M. J., Marcus, S. C., & Jensen, P. S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.6.1071 · Cited by 394
Cited by
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Storebø, O. J., Ramstad, E., Krogh, H. B., Nilausen, T. D., Skoog, M., Holmskov, M., Rosendal, S., Groth, C., Magnusson, F. L., Moreira-Maia, C. R., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009885.pub2 · Cited by 347
Storebø, O. J., Pedersen, N., Ramstad, E., Kielsholm, M. L., Nielsen, S. S., Krogh, H. B., Moreira-Maia, C. R., Magnusson, F. L., Holmskov, M., Gerner, T., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012069.pub2 · Cited by 321
Lambez, B., Harwood-Gross, A., Golumbic, E. Z., & Rassovsky, Y. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.10.007 · Cited by 207
Ching, C., Eslick, G. D., & Poulton, A. S. (2019) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2019.0905 · Cited by 70
Metadata
- Authors
- Newcorn, J. H., Stein, M. A., & Cooper, K. M.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2010-06
- Volume
- 20
- Issue
- 3
- Pages
- 187-196
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2078203108
- Cited by
- 32
- References
- 19
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.